Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.
about
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsNanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugsAntihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approachesA report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage formspH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive DiffusionRole of the intestinal bile acid transporters in bile acid and drug dispositionIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesImpact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoproteinMembrane transporters in drug developmentSimultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic modelCase studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound.The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.Development and validation of a discriminative dissolution method for atorvastatin calcium tablets using in vivo data by LC and UV methodsA comparative evaluation of models to predict human intestinal metabolism from nonclinical data.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesRelationship between characteristics of medications and drug-induced liver disease phenotype and outcome.Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX).Pharmacokinetic/ pharmacodynamic-driven drug developmentG.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS.Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.BDDCS applied to over 900 drugs.Sotalol permeability in cultured-cell, rat intestine, and PAMPA system.Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development.Pharmacokinetics and drug interactions of eslicarbazepine acetate.Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!Mechanistic interpretation of conventional Michaelis-Menten parameters in a transporter system.Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification SystemThe Controversy over Generic Antiepileptic Drugs.Functional interactions between P-glycoprotein and CYP3A in drug metabolism.Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectivesBDDCS class prediction for new molecular entities.Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse.Interaction of acupuncture and electroacupuncture on the pharmacokinetics of aspirin and the effect of brain blood flow in rats.Role of P glycoprotein in absorption of novel antimalarial drugs.Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug developmentAutomated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness.
P2860
Q26764739-4DCFA0B0-D364-42F4-B096-705DDE8C1EBAQ26774831-AB6C4FC5-89CE-4934-A3D9-A58AB8CF6F7AQ26861570-5E6219D5-70BF-4B80-B9B5-35746629384FQ27027075-C517105E-D027-40F0-B97C-471237861B7FQ27314887-4FF4B0FB-AA94-40B8-B812-9CA15F2AA4CAQ28299162-6093247D-5A37-4C8E-8256-5FE12F6E71BCQ28388335-CCC6B934-146F-44F4-847F-5720721C1743Q28480909-6B007935-352D-4454-90EB-570B268A125DQ29616802-8548DD31-B57F-4993-B590-955920399858Q30511951-C510064C-76E7-4093-A0D2-BF8BAC6DF446Q30576914-ED475E11-F214-4A46-832B-0B5258CC858AQ30662113-EAB89D99-384C-4A0D-A541-C9E71FE2B504Q30670381-84830397-28E3-4816-AE6C-BE3EE8C63C00Q30699630-0D980B43-8B8F-4F00-A374-487957B9C172Q31159063-4E88F4ED-92E6-4F66-990E-8FDA8E61B1BBQ33683206-24B61B6C-3F53-4029-A80D-2935F994D067Q33784830-4688E48E-F560-49F6-896A-5A4EF2F7D1B8Q33985923-52DD0363-B51A-4039-9723-D79CD64CE70EQ34051505-D5C0E2ED-27F8-4BAE-B1BD-4BE4BE5CDC80Q34099761-8E07F48E-5290-4A0E-8F12-9DBE302D9C6FQ34190909-2CF969A1-DE5A-498C-A3E0-69BB24C1EAE3Q34206152-A64BECDC-47A8-4408-8EDA-4C9670A9F4FDQ34206833-34F60014-D207-430D-9098-FABA4C92585AQ34226780-120E438F-C7A4-4F47-BF1D-94D7EB4C0747Q34273688-83070E97-F436-475F-8413-A047B90FFA50Q34276263-CCB6FA0A-9174-4A13-9698-CDCFC8BBDC23Q34289184-DB892A3C-E682-46AA-A6BF-72E2690DDE4BQ34378865-33DFF091-35C8-41B1-B309-DBAF5AF63369Q34381329-F0EEFD35-94F9-4E51-82C6-8E24EAEF7870Q34476865-3FAF5A74-D35B-41E1-9161-4B3983C7D6B9Q34550483-5CB45993-EBF8-4E83-9165-03A5360FAEB6Q34632445-893BFBDF-616C-44F3-9EF0-13560930E64EQ34634883-843416AA-A564-49CE-A33D-E0849DDCCCF3Q34646772-02D54850-2F55-4612-ACE7-A386C6F9E7C5Q34969837-76F689B3-E4F7-47C6-9717-4824EC108EBFQ35002429-C821ADFE-A24D-4E57-8EF4-A1A6237A9D7DQ35076545-4DD97CFE-DD6D-432D-B640-F69EB1C0A7BCQ35091572-87D8A205-335A-4E2A-82BC-1E53A9FBD25DQ35153417-6F666E7B-50B4-40FA-B077-8215AAD40E4EQ35176797-9145D294-074D-48A2-ADCF-A50D2454A232
P2860
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Predicting drug disposition vi ...... osition classification system.
@ast
Predicting drug disposition vi ...... osition classification system.
@en
Predicting drug disposition vi ...... osition classification system.
@nl
type
label
Predicting drug disposition vi ...... osition classification system.
@ast
Predicting drug disposition vi ...... osition classification system.
@en
Predicting drug disposition vi ...... osition classification system.
@nl
prefLabel
Predicting drug disposition vi ...... osition classification system.
@ast
Predicting drug disposition vi ...... osition classification system.
@en
Predicting drug disposition vi ...... osition classification system.
@nl
P1476
Predicting drug disposition vi ...... osition classification system.
@en
P2093
Chi-Yuan Wu
Leslie Z Benet
P356
10.1007/S11095-004-9004-4
P577
2005-01-01T00:00:00Z